Similar articles

• Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.

  Yagihashi T, Mizuno M, Chino B, Sato Y, Sakuma K, Takebayashi T, Takao T, Kosaki K. Yagihashi T, et al. Hum Psychopharmacol. 2009 Jun;24(4):301-8. doi: 10.1002/hup.1025. Hum Psychopharmacol. 2009. PMID: 19387994
• CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment.

  Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, Dorado P, Vaquero-Lorenzo C, Fernandez-Piqueras J, Llerena A, Abad-Santos F, Baca-García E, Dal-Ré R, Ayuso C; Spanish Consortium of Pharmacogenetics Research in Schizophrenia. Almoguera B, et al. Pharmacogenet Genomics. 2013 Nov;23(11):627-30. doi: 10.1097/FPC.0b013e3283659a94. Pharmacogenet Genomics. 2013. PMID: 24026091
• Risperidone plasma levels, clinical response and side-effects.

  Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Müller-Arends A, Weber K, Zach J, Müller N, Möller HJ. Riedel M, et al. Eur Arch Psychiatry Clin Neurosci. 2005 Aug;255(4):261-8. doi: 10.1007/s00406-004-0556-4. Epub 2004 Nov 29. Eur Arch Psychiatry Clin Neurosci. 2005. PMID: 15565299 Clinical Trial.
• A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part I.

  de Leon J, Sandson NB, Cozza KL. de Leon J, et al. Psychosomatics. 2008 May-Jun;49(3):258-70. doi: 10.1176/appi.psy.49.3.258. Psychosomatics. 2008. PMID: 18448784 Review.
• Pharmacogenetics of classical and new antipsychotic drugs.

  Otani K, Aoshima T. Otani K, et al. Ther Drug Monit. 2000 Feb;22(1):118-21. doi: 10.1097/00007691-200002000-00025. Ther Drug Monit. 2000. PMID: 10688273 Review.